Thursday, July 30

Browsing: RP1Nivolumab

Survivors

RP1/Nivolumab Shows OS Benefit in Anti-PD-1-Progressed Melanoma

By NewsCancerJune 1, 20260

Deep and durable responses were noted with vusolimogene oderparepvec (RP1) plus nivolumab (Opdivo) for patients with advanced melanoma who had…

Diagnosis

By NewsCancerApril 15, 20260

Sarah Weiss, MD, provided an in-depth look at the clinical activity of the oncolytic immunotherapy vusolimogene oderparepvec (RP1) in combination…

Diagnosis

By NewsCancerApril 10, 20260

The FDA has given a second complete response letter (CRL) to vusolimogene oderparepvec (RP1) in combination with nivolumab (Opdivo) for…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.